Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Venoglobulin-I is an intravenous immune globulin (IVIG) preparation made from pooled human plasma containing a high concentration of immunoglobulin G (IgG) antibodies. It is used to strengthen the body's natural defense system in individuals with weakened immune systems, such as those with primary immunodeficiency disorders. Venoglobulin-I is also indicated for increasing platelet counts in patients with idiopathic thrombocytopenic purpura (ITP), and may be used for other conditions including chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy, dermatomyositis, and prevention of vascular complications in Kawasaki syndrome. The mechanism of action involves providing passive immunity by supplying exogenous IgG antibodies that neutralize pathogens and modulate immune responses through multiple pathways, including Fc receptor blockade, complement modulation, suppression of pathogenic autoantibodies, and anti-inflammatory effects[10][1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on venoglobulin-i.